Siemens IMMULITE 2000 Mode D'emploi page 5

Lipemia: Presence of triglycerides in
concentrations up to 3000 mg/dL has no
effect on results, within the precision of the
assay.
Alternate Sample Type: To assess the
effect of alternate sample types, blood
was collected from 16 volunteers into
plain, heparinized, EDTA and Becton
®
Dickinson SST vacutainer tubes. Equal
volumes of the matched samples were
spiked with various concentrations of
calcitonin, to obtain values throughout the
calibration range of the assay, and then
assayed by the IMMULITE 2000
Calcitonin procedure.
(Heparin) = 0.99 (Serum) – 3.6 pg/mL
r = 0.999
(EDTA) = 0.79 (Serum) – 16.1 pg/mL
r = 0.993
(SST) = 1.02 (Plain Serum) – 5.2 pg/mL
r = 0.999
Means:
542 pg/mL (Plain Serum)
535 pg/mL (Heparin)
413 pg/mL (EDTA)
549 pg/mL (SST)
Method Comparison 1: The assay was
compared to IMMULITE Calcitonin on 150
samples. (Concentration range:
approximately up to 1500 pg/mL. See
graph.) By linear regression:
(IML 2000) = 1.08 (IML) – 9.6 pg/mL
r = 0.991
Means:
265 pg/mL (IMMULITE 2000)
253 pg/mL (IMMULITE)
Method Comparison 2: The assay was
also compared to a commercially available
assay (Kit A) on 67 samples.
(Concentration range: approximately up to
1500 pg/mL. See graph.) By linear
regression:
(IML 2000) = 0.81 (Kit A) – 0.4 pg/mL
r = 0.982
Means:
193 pg/mL (IMMULITE 2000)
239 pg/mL (Kit A)
References
1) Austin L, Heath H. Calcitonin; physiology and
pathophysiology. New Engl J Med
1981;304:269-78. 2) Body J-J, Heath H.
'Nonspecific' increases in plasma
immunoreactive calcitonin in healthy individuals.
Clin Chem 1984;30:511-4. 3) Catherwood BD,
Deftos LJ. General principles, problems, and
IMMULITE 2000 Calcitonin (PIL2KCL-18, 2018-03-15)
interpretation in the radioimmunoassay of
calcitonin and parathyroid hormone. In: Bikle
DD, editor. Assay of calcium-regulating
Hormones. New York: Springer-Verlag, 1983:
151-68. 4) Charpin C, et al. Calcitonin,
somatostatin and ACTH immunoreactive cells in
a case of familial bilateral thyroid medullary
carcinoma. Cancer 1982;50:1806-14. 5) Deftos
LJ, et al. Influence of age and sex on plasma
calcitonin in human beings. New Engl J Med
1980;302:1351-3. 6) Heath H, Sizemore GW.
Plasma calcitonin in normal man. J Clin Invest
1977;60:1135-40. 7) Heath H, Sizemore GW.
Radioimmunoassay for calcitonin. Clin Chem
1982;28:1219-26. 8) Hillyard C, et al. Familial
medullary thyroid carcinoma. Lancet
1978;i:1009-11. 9) Hillyard C, et al.
Immunoreactive calcitonin in leukaemia. Br Med
J 1979;2:1392-93. 10) Hillyard C, Stevenson J.
Calcitonin as a tumour marker. Ligand Rev 1980
(Spring);2(1):31-3. 11) Milhaud G. Ectopic
secretion of calcitonin. In: Pecile A, editor.
Calcitonin 1980. Amsterdam: Excerpta Medica,
1981: 154-69. 12) Mulder H, Hackeng WHL.
Ectopic secretion of calcitonin. Acta Med Scand
1978;204:253-6. 13) Mulder H, et al.
Hypercalcitoninaemia in patients with chronic
inflammatory disease. Neth J Med 1980;23:
129-31. 14) Parthemore J, Deftos LJ. Calcitonin
secretion in normal human subjects. J Clin
Endocrinol Metab 1978;47:184-8. 15) Schwartz
KE, et al. Calcitonin in nonthyroidal cancer. J
Clin Endocrinol Metab 1979;49:438-44.
16) Sizemore GW, Go VLW. Stimulation tests
for diagnosis of medullary thyroid carcinoma.
Mayo Clin Proc 1975;50:53-6. 17) Stepanas AV,
et al. Medullary thyroid carcinoma; importance of
serial serum calcitonin measurements. Cancer
1979;43:825-37. 18) Toffaletti J. Calcitonin.
Clinical Chemistry News 1984 (July);10(7):20-1,
27. 19) Wallach S, et al. Plasma calcitonin as a
marker of disease activity in patients with small
cell carcinoma of the lung. J Clin Endocrinol
Metab 1981;53:602-6. 20) Wells SA.
Provocative agents and the diagnosis of
medullary carcinoma of the thyroid gland. Ann
Surg 1978;188:139-41. 21) Wells SA, et al. The
importance of early diagnosis in patients with
hereditary medullary thyroid carcinoma. Ann
Surg 1982;195:595-9. 22) National Committee
for Clinical Laboratory Standards. Procedures
for the collection of diagnostic blood specimens
by venipuncture; approved standard. 4th ed.
NCCLS Document H3-A4, Wayne, PA: NCCLS,
1998. 23) Tietz NW, editor. Clincal guide to
laboratory tests. 3nd ed. Philadelphia: W.B.
Saunders 1995: 98. 24) Golzman D, Tischler
AS. Characterization of the immunochemical
forms of calcitonin released by a medullary
thyroid carcinoma in tissue culture. J Clin Invest
1978 Feb; 61:449-58. 25) Becker KL, Snider
RH, Silva OL, Moore CF. Calcitonin
heterogeneity in lung cancer and medullary
thyroid cancer. Acta Endocrinol 1978 Sep;
89(1):89-99. 26) Zajac JD, Martin TJ, Hudson P,
Niall H, Jacobs JW. Biosynthesis of calcitonin by
human lung cancer cells. Endocrinology 1985
5